February 26, 2023
3 min watch
Save
Adjuvant chemotherapy extends survival in pancreatic cancer
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
Adjuvant chemotherapy appeared associated with a significant survival benefit among patients with pancreatic ductal adenocarcinoma who underwent multiagent neoadjuvant chemotherapy and resection, according to study results.
Investigators observed the survival benefit regardless patients lymph node status or resection margins.
Healio spoke with Marco Del Chiaro, MD, division chief of surgical oncology with University of Colorado’s department of surgery, and visiting researcher Toshitaka Sugawara, MD, PhD, about the findings and their potential implications.
Published by:
Sources/Disclosures
Collapse
Disclosures:
Japan Society for the Promotion of Science Overseas Challenge Program for Young Researchers and Mochida Memorial Foundation for Medical and Pharmaceutical Research supported this study. Del Chiaro reports an industry grant from Haemonetics and a co-principal investigator role with a Boston Scientific-sponsored study outside the current work. All other authors report no relevant financial disclosures.
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.